Carolina M. Reyes, PhD

home / authors / carolina-m-reyes-phd

Articles

Site Logo

Lung Cancer: Copayments and Behavior Following Erlotinib Formulary Tier Change

Nicole M. Engel-Nitz, PhD;Sacha Satram-Hoang, PhD;Feng Cao, PhD;Carolina M. Reyes, PhD
November 13th 2012

Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.

Read More

Site Logo

Costs Associated With Second-Line Therapies for Lung Cancer

Stephen Lash, PharmD;April Teitelbaum, MD;Henry J. Henk, PhD;Carolina M. Reyes, PhD;Lucinda Benn, MBA
February 2nd 2011

Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD